Showing 1 posts of 1 posts found.
Swiss fine chemicals firm Lonza has secured two new contracts for its contract manufacturing division for monoclonal antibodies to treat …
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease